1. An immunogenic composition that contains: a) a C. difficile polypeptide selected from Dif44 and Dif208, b) a nucleic acid molecule encoding the polypeptide a), and / or c) an antibody capable of binding to the polypeptide a). 2. The immunogenic composition of claim 1, further comprising at least one C. difficile ToxB-GT antigen and at least one C. difficile TcdA antigen, nucleic acid molecules encoding said antigens and / or antibodies capable of binding to said antigens. 3. The immunogenic composition of claim 2, wherein the ToxB-GT antigen and / or the TcdA antigen are neutralized. The immunogenic composition according to claim 1, wherein said Dif44 polypeptide contains the amino acid sequence, a) with an identity of 80% or more with SEQ ID NO: 139 or SEQ ID NO: 79； and / or b) which is a fragment of at least 7 consecutive amino acids of SEQ ID NO: 139 or SEQ ID NO: 79, or a polypeptide with an identity of 80% or more with SEQ ID NO: 139 or SEQ ID NO: 79, and which contains the epitope of SEQ ID NO: 139 or SEQ ID NO: 79.5. The immunogenic composition according to claim 1, wherein said Dif208 polypeptide contains the amino acid sequence, a) with an identity of 80% or more with SEQ ID NO: 433 or SEQ ID NO: 133； and / or b) which is a fragment of at least 7 consecutive amino acids of SEQ ID NO: 433 or SEQ ID NO: 133, or a polypeptide with an identity of 80% or more with SEQ ID NO: 433 or SEQ ID NO: 133, and which contains the epitope of SEQ ID NO: 433 or SEQ ID NO: 133.6. The immunogenic composition of claim 5, wherein said fragment contains an amino acid sequence with an identity of 80% or more with SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 171 or SEQ ID NO: 173.7. The immunogenic composition of claim 2, wherein the ToxB-GT antigen is a polypeptide that contains or consists of an amino acid sequence, a) with an identity of 80% or more with SEQ ID NO: 18 or SEQ ID NO: 60； and / or b) which is a fragment of at least 7 consecutive amino acids of SEQ ID NO: 18 or SE
